ALNYLAM PHARMACEUTICALS, INC.
No SEC Form 4 filings for $ALNY in the last 30 days.
See all $ALNY insider activity →Alnylam Pharmaceuticals (ALNY) cut its full-year 2026 TTR product sales guidance by about $200 million, citing normalized growth, and is also facing a securities law investigation. The stock fell 19.25% over 30 days and 43.24% year to date. Simply Wall St’s “undervalued” narrative sets a fair value of $434.72 versus $227.12 last close.
Alnylam reported $1.01B in Q2 Amvuttra sales, below consensus, and trimmed 2026 revenue guidance for its transthyretin franchise by $200M to $4.2B-$4.5B, citing normalized second-line demand. The article also notes AbbVie’s Imbruvica Q2 $532M vs ~$533M, Merck’s vaccines slightly below expectations, and Roche’s Vabysmo $1.27B vs consensus.
Alnylam (ALNY) reported Q2 2026 net product revenues of $1.2B, up 74%, driven by AMVUTTRA uptake in ATTR cardiomyopathy. TTR net product revenues were $1.03B, up 89%, and the company raised AMVUTTRA run rate to over $4B annually. It lowered 2026 product guidance to $4.7B-$5.1B and revised collaboration/royalty guidance to $575M-$625M.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ALNY (ALNYLAM PHARMACEUTICALS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent ALNY coverage spans earnings, market movers and sector analysis.
Guidance reduction plus legal scrutiny increases downside risk to TTR growth and margin assumptions, pressuring the valuation narrative.
Guidance cut tied to demand normalization raises near-term revenue risk for the transthyretin franchise.
Guidance cut shifts near-term revenue expectations while AMVUTTRA run-rate and first-line penetration support a longer-duration growth narrative.
The immediate catalyst is a fresh sell-side upgrade with a specific target, reframing the stock as oversold versus pipeline value.
The Wainua failure is a negative catalyst for market perception of nucresiran’s ATTR-CM prospects, increasing uncertainty around endpoint sensitivity and effect size.
alphai scores every news story that mentions ALNY with an AI model for sentiment and relevance, and aggregates insider trades from ALNYLAM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alnylam Pharmaceuticals (ALNY) cut its full-year 2026 TTR product sales guidance by about $200 million, citing normalized growth, and is also facing a securities law investigation. The stock fell 19.25% over 30 days and 43.24% year to date. Simply Wall St’s “undervalued” narrative sets a fair value of $434.72 versus $227.12 last close.
6 min readAlnylam reported $1.01B in Q2 Amvuttra sales, below consensus, and trimmed 2026 revenue guidance for its transthyretin franchise by $200M to $4.2B-$4.5B, citing normalized second-line demand. The article also notes AbbVie’s Imbruvica Q2 $532M vs ~$533M, Merck’s vaccines slightly below expectations, and Roche’s Vabysmo $1.27B vs consensus.
7 min readAlnylam (ALNY) reported Q2 2026 net product revenues of $1.2B, up 74%, driven by AMVUTTRA uptake in ATTR cardiomyopathy. TTR net product revenues were $1.03B, up 89%, and the company raised AMVUTTRA run rate to over $4B annually. It lowered 2026 product guidance to $4.7B-$5.1B and revised collaboration/royalty guidance to $575M-$625M.
7 min readAlnylam Pharmaceuticals shares rose 1.7% in pre-open to $209.1 after Raymond James upgraded the stock from Outperform to Strong Buy and set a $420 price target. The upgrade followed a post–Q2 selloff tied to reduced ATTR franchise guidance. Other banks issued constructive notes. The S&P 500 and Dow were up.
3 min readAstraZeneca and Ionis’ Wainua failed to show significant cardiovascular benefit in a Phase 3 trial in ATTR-CM, an outcome analysts said likely reduces odds of filing for that indication. The article reviews other ATTR-CM programs: AstraZeneca’s cliramitug (DepleTTR-CM, ~1,200 patients), Novo Nordisk’s coramitug (CLEOPATTRA, recruiting), Alnylam’s nucresiran (TRITON-CM, completion 2030), and Intellia’s nex-z (MAGNITUDE).
7 min readAlnylam reported Q2 2026 AMVUTTRA net product revenue of $1.01B, up 106% year over year, and total quarterly product revenue of $1.17B. Combined TTR revenue was $1.03B. Despite results, Alnylam cut 2026 TTR product revenue guidance to $4.2B-$4.5B and total net product revenue to $4.7B-$5.1B, citing normalization of second-line demand. Total Q2 revenue rose to $1.29B.
6 min readAlnylam Pharmaceuticals shares fell nearly 30% after the company lowered 2026 revenue guidance for its transthyretin amyloidosis drugs Amvuttra and Onpattro by $200 million. The estimate was cut to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing normalized demand after an early launch spike. Amvuttra quarterly sales were $1.01 billion.
4 min readKirby McInerney LLP said it is investigating potential securities fraud claims involving Alnylam Pharmaceuticals (NASDAQ: ALNY). The probe follows Alnylam’s July 30, 2026 Q2 results, including lowered full-year 2026 TTR product sales guidance and a roughly $200 million reduction in projected TTR net product revenues. Alnylam shares fell about 28% to $205.48.
4 min readUS stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.
7 min readThursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Josh Brodsky Chief Executive Officer - Yvonne Greenstreet Chief Financial Officer - Jeff Poulton Chief Commercial Officer - Tolga Tanguler Chief Research and Development Officer - Pushkal Garg TAKEAWAYS Total Net Product Revenues -- $1.2 billion, representing 74% growth versus the second quarter of last year driven by the uptake of AMVUTTRA in ATTR cardiomyopathy.
6 min read
